DK1732562T3 - Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil - Google Patents

Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil

Info

Publication number: DK1732562T3
Authority: DK; Denmark
Prior art keywords: modulators; metabolism; treatment; disorders related; substituted pyridinyl
Prior art date: 2005-01-10

Application number

DK06733644T

Other languages

English (en)

Inventor

Amy Siu-Ting Wong

Young-Jun Shin

David Hurst

Robert M Jones

Juerg Lehmann

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-10

Filing date

2006-01-09

Publication date

2008-04-28

2006-01-09 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2008-04-28 Application granted granted Critical

2008-04-28 Publication of DK1732562T3 publication Critical patent/DK1732562T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK06733644T 2005-01-10 2006-01-09 Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil DK1732562T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US64284005P	2005-01-10	2005-01-10
PCT/US2006/000567 WO2006083491A2 (en)	2005-01-10	2006-01-09	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Publications (1)

Publication Number	Publication Date
DK1732562T3 true DK1732562T3 (da)	2008-04-28

Family

ID=36755755

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK07023528.8T DK1911756T3 (da)	2005-01-10	2006-01-09	Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil
DK06733644T DK1732562T3 (da)	2005-01-10	2006-01-09	Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK07023528.8T DK1911756T3 (da)	2005-01-10	2006-01-09	Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil

Country Status (36)

Country	Link
US (3)	US20060155128A1 (da)
EP (2)	EP1732562B1 (da)
JP (1)	JP2008526882A (da)
KR (1)	KR20070098907A (da)
CN (2)	CN102125555A (da)
AR (1)	AR054320A1 (da)
AT (2)	ATE446293T1 (da)
AU (1)	AU2006211583C1 (da)
BR (1)	BRPI0606704A (da)
CA (1)	CA2594466A1 (da)
CR (1)	CR9225A (da)
CY (2)	CY1107215T1 (da)
DE (2)	DE602006000339T2 (da)
DK (2)	DK1911756T3 (da)
EA (1)	EA015714B1 (da)
ES (2)	ES2299167T4 (da)
GE (1)	GEP20094828B (da)
GT (1)	GT200600006A (da)
HN (2)	HN2006000969A (da)
HR (2)	HRP20080113T3 (da)
IL (1)	IL184363A0 (da)
MX (1)	MX2007008402A (da)
MY (1)	MY148521A (da)
NI (1)	NI200700169A (da)
NO (1)	NO20073806L (da)
NZ (1)	NZ556220A (da)
PE (2)	PE20060857A1 (da)
PL (2)	PL1911756T3 (da)
PT (2)	PT1732562E (da)
RS (2)	RS50540B (da)
SG (1)	SG158875A1 (da)
SI (2)	SI1911756T1 (da)
TW (1)	TW200637845A (da)
UA (1)	UA89812C2 (da)
WO (1)	WO2006083491A2 (da)
ZA (1)	ZA200705471B (da)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2004205642C1 (en)	2003-01-14	2012-01-12	Arena Pharmaceuticals, Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
KR20050106033A (ko) *	2003-02-24	2005-11-08	아레나 파마슈티칼스, 인크.	글루코스 대사 조절제로서의 페닐- 및피리딜피페리딘-유도체
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2005121121A2 (en) *	2004-06-04	2005-12-22	Arena Pharmaceuticals, Inc.	Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DOP2006000010A (es)	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US20090099200A1 (en) *	2005-06-09	2009-04-16	Chun Sing Li	Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
BRPI0611784A2 (pt)	2005-06-14	2010-09-28	Hoffmann La Roche	compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e utilização desses compostos
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1931654B1 (en) *	2005-09-16	2009-04-22	Arena Pharmaceuticals, Inc.	Modulators of metabolism and the treatment of disorders related thereto
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US7833730B2 (en) *	2006-04-11	2010-11-16	Arena Pharmaceuticals, Inc.	Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
NZ573360A (en)	2006-05-04	2012-08-31	Boehringer Ingelheim Int	Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
TW200811147A (en) *	2006-07-06	2008-03-01	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) *	2006-07-06	2008-03-01	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2144902B1 (en)	2007-05-04	2012-05-16	Bristol-Myers Squibb Company	[6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
JP2010526146A (ja)	2007-05-04	2010-07-29	ブリストル−マイヤーズスクイブカンパニー	［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
CA2693444A1 (en)	2007-07-17	2009-01-22	Bristol-Myers Squibb Company	Method for modulating gpr119 g protein-coupled receptor and selected compounds
AU2008279447A1 (en)	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2499018T3 (es) *	2007-09-20	2014-09-26	Irm Llc	Compuestos y composiciones como moduladores de la actividad de GPR119
EP2210886B1 (en) *	2007-10-16	2015-09-23	Daiichi Sankyo Company, Limited	Pyrimidyl indoline compound
WO2009055331A2 (en) *	2007-10-22	2009-04-30	Schering Corporation	Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
EP2259678A4 (en) *	2008-02-29	2011-07-27	Cylene Pharmaceuticals Inc	PROTEIN KINASE MODULATORS
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (en) *	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
KR20110026481A (ko) *	2008-06-20	2011-03-15	메타볼렉스, 인코포레이티드	아릴 ｇｐｒ１１９ 작동약 및 이의 용도
TW201006821A (en) *	2008-07-16	2010-02-16	Bristol Myers Squibb Co	Pyridone and pyridazone analogues as GPR119 modulators
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
AU2009290911A1 (en)	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010059384A1 (en) *	2008-10-30	2010-05-27	Janssen Pharmaceutica Nv	Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
WO2010059385A1 (en) *	2008-10-30	2010-05-27	Janssen Pharmaceutica Nv	Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidne derivatives useful as gdir agonists
US20110160222A1 (en) *	2008-11-26	2011-06-30	Metabolex, Inc.	Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
US8722882B2 (en)	2008-12-23	2014-05-13	Merck Sharp & Dohme Corp.	Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes
AU2009330208A1 (en)	2008-12-23	2011-08-04	Merck Sharp & Dohme Corp.	Bicyclic heterocycle derivatives and methods of use thereof
MX2011006713A (es)	2008-12-23	2011-07-13	Boehringer Ingelheim Int	Formas salinas de compuesto organico.
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US8410089B2 (en)	2009-02-18	2013-04-02	Takeda Pharmaceutical Company Limited	Fused heterocyclic ring compound
TW201039827A (en) *	2009-04-15	2010-11-16	Daiichi Sankyo Co Ltd	Indoline compound
US20110015215A1 (en) *	2009-05-20	2011-01-20	Paul Deghetto	Crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
US20100298362A1 (en) *	2009-05-20	2010-11-25	Xun Li	Process for the preparation of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
US8481731B2 (en)	2009-06-24	2013-07-09	Boehringer Ingelheim International Gmbh	Compounds, pharmaceutical composition and methods relating thereto
AR077215A1 (es)	2009-06-24	2011-08-10	Boehringer Ingelheim Int	Derivados de piperidina, composiciones farmaceuticas y metodos relacionados con ellos
WO2011041154A1 (en)	2009-10-01	2011-04-07	Metabolex, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
AU2010323068B2 (en)	2009-11-27	2015-09-03	Boehringer Ingelheim International Gmbh	Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
CA2786994C (en)	2010-01-27	2018-01-16	Arena Pharmaceuticals, Inc.	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en)	2010-03-18	2011-09-22	Boehringer Ingelheim International Gmbh	Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US8415367B2 (en)	2010-04-08	2013-04-09	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
KR101927068B1 (ko)	2010-05-05	2018-12-10	베링거 인겔하임 인터내셔날 게엠베하	체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
BR112012028445A2 (pt)	2010-05-06	2016-07-19	Bristol Myers Squibb Co	compostos de heteroarila bicíclica como moduladores de gpr119
WO2011140161A1 (en)	2010-05-06	2011-11-10	Bristol-Myers Squibb Company	Benzofuranyl analogues as gpr119 modulators
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2011163090A1 (en)	2010-06-23	2011-12-29	Metabolex, Inc.	Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2011161161A1 (en)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Diabetes therapy
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012025811A1 (en)	2010-08-23	2012-03-01	Lupin Limited	Indolylpyrimidines as modulators of gpr119
IN2013DN02552A (da)	2010-09-01	2015-08-07	Arena Pharm Inc
AU2011296014A1 (en)	2010-09-01	2013-04-04	Arena Pharmaceuticals, Inc.	Salts of lorcaserin with optically active acids
EP3485878A1 (en)	2010-09-01	2019-05-22	Arena Pharmaceuticals, Inc.	Modified-release dosage forms of 5-ht2c agonists useful for weight management
US9365521B2 (en)	2010-09-01	2016-06-14	Arena Pharmaceuticals, Inc.	Non-hygroscopic salts of 5-HT2C agonists
CA2812061A1 (en)	2010-09-22	2012-03-29	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2625177B1 (en) *	2010-10-08	2015-07-29	Cadila Healthcare Limited	Novel gpr 119 agonists
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
CA2818050A1 (en)	2010-11-26	2012-05-31	Lupin Limited	Bicyclic gpr119 modulators
EP2661438A4 (en) *	2011-01-03	2014-06-11	Hanmi Pharm Ind Co Ltd	NEW BICYCLIC COMPOUND FOR MODULATING G-PROTEIN-COUPLED RECEPTORS
US20140038889A1 (en) *	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
EP2718279B1 (en)	2011-06-09	2016-08-10	Rhizen Pharmaceuticals SA	Novel compounds as modulators of gpr-119
WO2013010964A1 (en)	2011-07-15	2013-01-24	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP2849755A1 (en)	2012-05-14	2015-03-25	Boehringer Ingelheim International GmbH	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en)	2012-05-14	2022-09-14	Boehringer Ingelheim International GmbH	Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP2850073B1 (en)	2012-05-16	2017-07-19	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN105101829B (zh) *	2013-03-15	2017-11-10	耐克创新有限合伙公司	包括包含波涛结构的鞋底结构的鞋类物品
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
MX386419B (es)	2015-01-06	2025-03-18	Arena Pharm Inc	Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
MA42807A (fr)	2015-06-22	2018-07-25	Arena Pharm Inc	Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
JP2019517542A (ja)	2016-06-10	2019-06-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	リナグリプチンおよびメトホルミンの組合せ
CA3032432A1 (en)	2016-08-03	2018-02-08	Charles A. Mcwherter	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
JP7187037B2 (ja) *	2016-09-07	2022-12-12	ザリージェンツオブザユニバーシティオブカリフォルニア	ｐ－タウを減少させ、認知機能を改善させるアロステリック副腎皮質刺激ホルモン放出因子受容体１（ＣＲＦＲ１）アンタゴニスト
KR20190116416A (ko)	2017-02-16	2019-10-14	아레나 파마슈티칼스, 인크.	원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
US20200129511A1 (en)	2017-06-19	2020-04-30	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of nafld and nash
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
CN108658871B (zh) *	2018-06-19	2020-10-30	舞阳威森生物医药有限公司	周效磺胺中间体4,6-二氯-5-甲氧基嘧啶的制备方法
CN108892635A (zh) *	2018-09-07	2018-11-27	江苏工程职业技术学院	一种西沙必利关键中间体的制备方法

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US618777A (en) *		1899-01-31		Window
US427174A (en) *		1890-05-06		Minor c
CH389134A (de)	1960-03-15	1965-03-15	Ciba Geigy	Verfahren zur Herstellung neuer Anthrachinonküpenfarbstoffe
CH478817A (de)	1965-10-22	1969-09-30	Ciba Geigy	Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen
CH480410A (de)	1967-01-09	1969-10-31	Geigy Ag J R	Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en)	1967-01-12	1975-01-14	Max Schellenbaum	N-2-ethylhexyl-n'-aryl ureas and preparation containing them
FR1593586A (da)	1967-10-17	1970-06-01
US3608087A (en)	1968-06-21	1971-09-21	Merck & Co Inc	Feed compositions
US3887329A (en)	1969-05-05	1975-06-03	Ciba Geigy Ag	Hexamethyl phosphotriamide-dye compositions
BE756953A (fr)	1969-10-02	1971-04-01	Merck & Co Inc	Potentialisation d'antibiotiques
US3686238A (en)	1970-01-19	1972-08-22	Syntex Corp	Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en)	1970-09-11	1974-12-03	Merck & Co Inc	Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3966744A (en)	1971-01-11	1976-06-29	Syva Company	Spin labeled compounds
US3690834A (en)	1971-01-11	1972-09-12	Syva Co	Ligand determination with spin labeled compounds by receptor displacement
DE2106585A1 (de)	1971-02-11	1972-08-24	Farbenfabriken Bayer Ag, 5090 Leverkusen	Aminothiodiazole und Thiodiazol-Azofarbstoffe
CH560197A5 (en)	1971-05-17	1975-03-27	Ciba Geigy Ag	2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides
CH558137A (de)	1971-05-17	1975-01-31	Ciba Geigy Ag	Mittel zur beeinflussung des pflanzenwachstums.
US3966764A (en)	1972-07-10	1976-06-29	Syva Company	Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en)	1972-10-20	1974-11-19	Dow Chemical Co	Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (da)	1972-11-16	1976-04-15	Ciba Geigy Ag
DE2340569C2 (de)	1973-08-10	1982-12-02	Bayer Ag, 5090 Leverkusen	Azofarbstoffe
AT340933B (de)	1973-08-20	1978-01-10	Thomae Gmbh Dr K	Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de)	1973-08-20	1975-03-06	Thomae Gmbh Dr K	Neue pyrimidinderivate und verfahren zu ihrer herstellung
CH584739A5 (da)	1973-12-21	1977-02-15	Ciba Geigy Ag
US4101541A (en)	1973-12-21	1978-07-18	Ciba-Geigy Corporation	3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
FR2258841B1 (da)	1974-01-29	1977-11-04	Ugine Kuhlmann
AT327605B (de)	1974-05-06	1976-02-10	Ciba Geigy Ag	Mittel zur hemmung des pflanzenwachstums
AU492126B2 (en)	1974-05-14	1975-11-20	Ciba-Geigy Ag	Nitropyrimidine derivatives
FR2306697A1 (fr)	1975-04-10	1976-11-05	Sogeras	Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
DE2731264A1 (de)	1977-07-11	1979-02-01	Boehringer Mannheim Gmbh	Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja)	1977-12-09	1985-09-02	コニカ株式会社	ハロゲン化銀カラ−写真感光材料
US4242507A (en)	1978-02-23	1980-12-30	Fujisawa Pharmaceutical Co., Ltd.	Sulfonic acid esters
DE2831580C2 (de) *	1978-07-18	1980-09-18	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren und Reagens zur Bestimmung von Glycerin
DE2831850A1 (de)	1978-07-20	1980-02-07	Basf Ag	N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel
DE2906603A1 (de)	1979-02-21	1980-09-04	Boehringer Mannheim Gmbh	N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
DOP1981004033A (es) *	1980-12-23	1990-12-29	Ciba Geigy Ag	Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
DE3334455A1 (de)	1983-03-04	1984-09-06	Bayer Ag, 5090 Leverkusen	Guanidin - derivate
ZA848275B (en) *	1983-12-28	1985-08-28	Degussa	New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3406329A1 (de)	1984-02-22	1985-08-22	Merck Patent Gmbh, 6100 Darmstadt	Pyridone
PH22302A (en)	1985-02-11	1988-07-22	Fujisawa Pharmaceutical Co	Piperidine compounds
AU601145B2 (en)	1985-03-01	1990-09-06	Duphar International Research B.V.	Benzoyl urea derivatives having anti-tumor activity
DE3601196A1 (de) *	1986-01-17	1987-07-23	Merck Patent Gmbh	1,4-dihydropyridine
CA1340284C (en)	1987-03-19	1998-12-22	Zeneca Inc.	Herbicidal substituted cyclic diones
DE68926687T2 (de)	1988-01-11	1997-03-06	Fuji Photo Film Co Ltd	Verfahren zur Erzeugung von extrem hochkontrastreichen negativen Bildern
CA2070978A1 (en)	1991-06-11	1992-12-12	William J. Greenlee	Cyclic renin inhibitors
EP0556889A1 (en)	1992-02-18	1993-08-25	Duphar International Research B.V	Method of preparing aryl(homo)piperazines
TW237456B (da)	1992-04-09	1995-01-01	Ciba Geigy
DE4241632A1 (de)	1992-12-10	1994-06-16	Thomae Gmbh Dr K	Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9400889D0 (en)	1994-01-18	1994-03-16	Sandoz Ltd	Novel compounds
TW574214B (en) *	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
MX9701765A (es) *	1994-09-09	1997-06-28	Nippon Shinyaku Co Ltd	Derivado heterociclico y medicina.
BR9509827A (pt)	1994-11-29	1997-09-30	Dainippon Pharmaceutical Co	Derivados de indol
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
US6956047B1 (en) *	1995-06-06	2005-10-18	Pfizer Inc.	Corticotropin releasing factor antagonists
US6403599B1 (en) *	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
CZ126598A3 (cs)	1995-10-26	1998-09-16	Mitsubishi-Tokyo Pharmaceuticals, Inc.	Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US5849759A (en)	1995-12-08	1998-12-15	Berlex Laboratories, Inc.	Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DE19602095A1 (de)	1996-01-22	1997-07-24	Bayer Ag	Halogenpyrimidine
US5948786A (en)	1996-04-12	1999-09-07	Sumitomo Pharmaceuticals Company, Limited	Piperidinylpyrimidine derivatives
AR008789A1 (es) *	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
US6008234A (en) *	1996-09-12	1999-12-28	Berlex Laboratories, Inc.	Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
NO980546L (no)	1997-02-11	1998-08-12	Lilly Co Eli	Farmas°ytiske midler
DE19737723A1 (de)	1997-08-14	1999-02-18	Bayer Ag	Methoximinomethyloxadiazine
US6187777B1 (en) *	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
JP2000038350A (ja)	1998-05-18	2000-02-08	Yoshitomi Pharmaceut Ind Ltd	糖尿病治療薬
US6239126B1 (en) *	1998-12-17	2001-05-29	American Home Products Corporation	Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
US6267985B1 (en) *	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
EP1040831A3 (en)	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU5020400A (en) *	1999-05-20	2000-12-12	E.I. Du Pont De Nemours And Company	Heteroaryloxypyrimidine insecticides and acaricides
EP1074549B1 (en)	1999-08-06	2003-11-19	F. Hoffmann-La Roche Ag	Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
US6414002B1 (en) *	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP2001089452A (ja)	1999-09-22	2001-04-03	Sankyo Co Ltd	ピリミジン誘導体
DE19962936A1 (de)	1999-12-24	2001-06-28	Bayer Ag	Neue beta-Aminosäureverbindungen als Integrinantagonisten
US6569879B2 (en) *	2000-02-18	2003-05-27	Merck & Co., Inc.	Aryloxyacetic acids for diabetes and lipid disorders
EP1287133B1 (en)	2000-05-18	2006-12-13	Bayer HealthCare AG	Regulation of human dopamine-like g protein-coupled receptor
US6620821B2 (en) *	2000-06-15	2003-09-16	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
CN1705649A (zh) *	2000-06-29	2005-12-07	艾伯特公司	芳基苯基杂环基硫醚衍生物及其作为抑制细胞粘附的抗炎和免疫抑制剂的用途
US20030224058A1 (en) *	2002-05-24	2003-12-04	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US7276249B2 (en) *	2002-05-24	2007-10-02	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
AU2002248221B2 (en) *	2000-10-31	2006-08-17	Merck & Co., Inc.	Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
US20020058026A1 (en) *	2000-11-13	2002-05-16	Milton Hammerly	HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
EP1340749A4 (en)	2000-11-17	2007-09-05	Takeda Pharmaceutical	ISOXAZOLE DERIVATIVES
US6525064B1 (en) *	2000-12-08	2003-02-25	3M Innovative Properties Company	Sulfonamido substituted imidazopyridines
US6545017B1 (en) *	2000-12-08	2003-04-08	3M Innovative Properties Company	Urea substituted imidazopyridines
US6545016B1 (en) *	2000-12-08	2003-04-08	3M Innovative Properties Company	Amide substituted imidazopyridines
ME00145B (me) *	2001-01-26	2010-10-10	Merck Sharp & Dohme	Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
WO2003002544A1 (en)	2001-06-26	2003-01-09	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of tnf-alpha expression
WO2004013997A1 (en)	2001-08-02	2004-02-12	Halliburton Energy Service, Inc.	Adaptive acoustic transmitter controller apparatus and method
GB0229931D0 (en)	2002-12-21	2003-01-29	Astrazeneca Ab	Therapeutic agents
US20070225351A1 (en) *	2002-01-11	2007-09-27	Lippa Arnold S	Methods and compositions for controlling body weight and appetite
US7057046B2 (en) *	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
WO2003103632A1 (en) *	2002-06-10	2003-12-18	Elan Pharma International, Ltd.	Nanoparticulate polycosanol formulations and novel polycosanol combinations
GB0214254D0 (en)	2002-06-20	2002-07-31	Glaxo Group Ltd	Chemical compounds
SE0201976D0 (sv)	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
EP1531832B1 (en)	2002-06-28	2009-04-15	Glykos Finland Oy	Therapeutic compositions for use in prophylaxis or treatment of diarrheas
US7071210B2 (en)	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en)	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
AU2003251869A1 (en)	2002-07-15	2004-02-02	Merck & Co., Inc.	Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US7524882B2 (en)	2002-07-30	2009-04-28	Merck & Co., Inc.	PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
ATE468851T1 (de)	2002-07-30	2010-06-15	Merck Sharp & Dohme	Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
BR0313255A (pt)	2002-08-08	2005-07-12	Amgen Inc	Composto, composição farmacêutica, uso de um composto e métodos de fabricar um medicamento e de preparar um composto
JP2006500378A (ja)	2002-08-21	2006-01-05	メルク　エンド　カムパニー　インコーポレーテッド	二元ＰＰＡＲα／γアゴニストとアンギオテンシンＩＩのＩ型受容体アンタゴニストを使用する併用療法
WO2004019869A2 (en)	2002-08-29	2004-03-11	Merck & Co., Inc.	Indoles having anti-diabetic activity
CA2495943C (en)	2002-08-29	2009-07-21	Merck & Co., Inc.	Indoles having anti-diabetic activity
WO2004033431A2 (en)	2002-10-04	2004-04-22	Arena Pharmaceuticals, Inc.	Hydroxypyrazoles for use against metabolic-related disorders
WO2004033710A2 (en)	2002-10-09	2004-04-22	Genaissance Pharmaceuticals, Inc.	Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
CA2503715A1 (en)	2002-10-30	2004-05-21	Merck & Co., Inc.	Kinase inhibitors
US7098235B2 (en) *	2002-11-14	2006-08-29	Bristol-Myers Squibb Co.	Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20040110241A1 (en) *	2002-12-06	2004-06-10	Segal Mark S.	Materials and methods for monitoring vascular endothelial function
AU2003299790A1 (en)	2002-12-20	2004-07-22	Bayer Pharmaceuticals Corporation	Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
JO2397B1 (en) *	2002-12-20	2007-06-17	ميرك شارب اند دوم كوربوريشن	Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004058727A1 (en)	2002-12-20	2004-07-15	Bayer Pharmaceuticals Corporation	Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2004205642C1 (en)	2003-01-14	2012-01-12	Arena Pharmaceuticals, Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
CA2512879A1 (en)	2003-01-17	2004-08-12	Soumya P. Sahoo	N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
KR20050106033A (ko) *	2003-02-24	2005-11-08	아레나 파마슈티칼스, 인크.	글루코스 대사 조절제로서의 페닐- 및피리딜피페리딘-유도체
JP2004269469A (ja)	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
JP2004269468A (ja)	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
HRP20050859A2 (en)	2003-03-28	2006-02-28	Pfizer Products Inc.	1,2,4-suptituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
TWI494102B (zh)	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
DK1475094T3 (da)	2003-05-06	2010-11-22	Univ Palackeho	Pyrazolo[4,3-d]pyrimidiner, fremgangsmåde til deres fremstilling samt deres anvendelse
US7083933B1 (en) *	2003-05-09	2006-08-01	Prosidion Limited	Methods for identification of modulators of OSGPR116 activity
WO2004110368A2 (en)	2003-06-06	2004-12-23	Merck & Co., Inc.	Combination therapy for the treatment of hypertension
US20070099884A1 (en)	2003-06-06	2007-05-03	Erondu Ngozi E	Combination therapy for the treatment of diabetes
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
BRPI0412689A (pt) *	2003-07-14	2006-10-03	Arena Pharm Inc	derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele
FI116461B (fi) *	2004-03-18	2005-11-30	Kone Corp	Menetelmä hissin asentamiseksi ja hissin toimituskokonaisuus
WO2005121121A2 (en) *	2004-06-04	2005-12-22	Arena Pharmaceuticals, Inc.	Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
JP4958787B2 (ja)	2004-09-20	2012-06-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
ATE481969T1 (de)	2004-10-01	2010-10-15	Merck Sharp & Dohme	Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
CN101084018B (zh)	2004-11-03	2013-12-18	艾尼纳制药公司	用于治疗胰岛素相关病症的gpr41和其调节剂
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es) *	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
CN101107245A (zh)	2005-01-19	2008-01-16	神经能质公司	经杂芳基取代的哌嗪-吡啶类似物
AU2006265840B2 (en)	2005-07-01	2010-02-11	Irm Llc	Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
TW200745055A (en)	2005-09-23	2007-12-16	Organon Nv	4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
CA2635531C (en)	2005-12-29	2014-06-17	Lexicon Pharmaceutical Inc.	Multicyclic amino acid derivatives and methods of their use
CA2637631C (en) *	2006-01-19	2014-04-29	Orchid Research Laboratories Limited	Pyrimidine compounds and uses thereof
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas

2006
- 2006-01-04 MY MYPI2010006219A patent/MY148521A/en unknown
- 2006-01-06 PE PE2006000046A patent/PE20060857A1/es not_active Application Discontinuation
- 2006-01-06 PE PE2009001073A patent/PE20091590A1/es not_active Application Discontinuation
- 2006-01-09 CN CN201010617617XA patent/CN102125555A/zh active Pending
- 2006-01-09 WO PCT/US2006/000567 patent/WO2006083491A2/en not_active Ceased
- 2006-01-09 RS RSP-2008/0068A patent/RS50540B/sr unknown
- 2006-01-09 PT PT06733644T patent/PT1732562E/pt unknown
- 2006-01-09 PL PL07023528T patent/PL1911756T3/pl unknown
- 2006-01-09 DE DE602006000339T patent/DE602006000339T2/de not_active Expired - Lifetime
- 2006-01-09 EP EP06733644A patent/EP1732562B1/en not_active Expired - Lifetime
- 2006-01-09 DE DE602006009946T patent/DE602006009946D1/de not_active Expired - Lifetime
- 2006-01-09 RS RSP-2009/0523A patent/RS51007B/sr unknown
- 2006-01-09 CN CNA2006800044893A patent/CN101115740A/zh active Pending
- 2006-01-09 BR BRPI0606704-2A patent/BRPI0606704A/pt not_active IP Right Cessation
- 2006-01-09 AR ARP060100071A patent/AR054320A1/es not_active Application Discontinuation
- 2006-01-09 PT PT07023528T patent/PT1911756E/pt unknown
- 2006-01-09 ES ES06733644T patent/ES2299167T4/es not_active Expired - Lifetime
- 2006-01-09 AT AT07023528T patent/ATE446293T1/de active
- 2006-01-09 MX MX2007008402A patent/MX2007008402A/es active IP Right Grant
- 2006-01-09 HN HN2006000969A patent/HN2006000969A/es unknown
- 2006-01-09 GE GEAP200611119A patent/GEP20094828B/en unknown
- 2006-01-09 ES ES07023528T patent/ES2333824T4/es not_active Expired - Lifetime
- 2006-01-09 HR HR20080113T patent/HRP20080113T3/xx unknown
- 2006-01-09 TW TW095100772A patent/TW200637845A/zh unknown
- 2006-01-09 NZ NZ556220A patent/NZ556220A/en not_active IP Right Cessation
- 2006-01-09 EP EP07023528A patent/EP1911756B9/en not_active Expired - Lifetime
- 2006-01-09 UA UAA200709148A patent/UA89812C2/ru unknown
- 2006-01-09 SI SI200630527T patent/SI1911756T1/sl unknown
- 2006-01-09 SI SI200630025T patent/SI1732562T1/sl unknown
- 2006-01-09 PL PL06733644T patent/PL1732562T3/pl unknown
- 2006-01-09 JP JP2007550520A patent/JP2008526882A/ja active Pending
- 2006-01-09 AT AT06733644T patent/ATE381558T1/de active
- 2006-01-09 SG SG201000207-9A patent/SG158875A1/en unknown
- 2006-01-09 US US11/327,896 patent/US20060155128A1/en not_active Abandoned
- 2006-01-09 DK DK07023528.8T patent/DK1911756T3/da active
- 2006-01-09 GT GT200600006A patent/GT200600006A/es unknown
- 2006-01-09 DK DK06733644T patent/DK1732562T3/da active
- 2006-01-09 CA CA002594466A patent/CA2594466A1/en not_active Abandoned
- 2006-01-09 EA EA200701471A patent/EA015714B1/ru not_active IP Right Cessation
- 2006-01-09 AU AU2006211583A patent/AU2006211583C1/en not_active Ceased
- 2006-01-09 KR KR1020077018314A patent/KR20070098907A/ko not_active Ceased
- 2006-07-06 US US11/482,777 patent/US8362248B2/en active Active
- 2006-11-20 US US11/601,927 patent/US20070078150A1/en not_active Abandoned
2007
- 2007-07-02 IL IL184363A patent/IL184363A0/en unknown
- 2007-07-03 CR CR9225A patent/CR9225A/es not_active Application Discontinuation
- 2007-07-04 NI NI200700169A patent/NI200700169A/es unknown
- 2007-07-04 ZA ZA200705471A patent/ZA200705471B/en unknown
- 2007-07-20 NO NO20073806A patent/NO20073806L/no not_active Application Discontinuation
2008
- 2008-02-27 CY CY20081100225T patent/CY1107215T1/el unknown
2009
- 2009-12-31 CY CY20091101355T patent/CY1109696T1/el unknown
2010
- 2010-01-07 HR HR20100008T patent/HRP20100008T1/hr unknown
- 2010-03-05 HN HN2010000430A patent/HN2010000430A/es unknown

Also Published As

Publication number	Publication date
RS50540B (sr)	2010-05-07
DE602006009946D1 (de)	2009-12-03
HK1094542A1 (en)	2007-04-04
ES2333824T4 (es)	2011-03-02
WO2006083491A2 (en)	2006-08-10
CN102125555A (zh)	2011-07-20
EP1732562B1 (en)	2007-12-19
EA200701471A1 (ru)	2008-02-28
ES2299167T3 (es)	2008-05-16
TW200637845A (en)	2006-11-01
EP1732562A2 (en)	2006-12-20
PE20060857A1 (es)	2006-09-02
MY148521A (en)	2013-04-30
KR20070098907A (ko)	2007-10-05
ZA200705471B (en)	2008-07-30
IL184363A0 (en)	2007-10-31
US8362248B2 (en)	2013-01-29
HRP20100008T1 (hr)	2010-02-28
CY1107215T1 (el)	2012-11-21
ES2299167T4 (es)	2011-02-18
SI1911756T1 (sl)	2010-02-26
EA015714B1 (ru)	2011-10-31
PE20091590A1 (es)	2009-10-23
PL1732562T3 (pl)	2008-04-30
SG158875A1 (en)	2010-02-26
ES2333824T3 (es)	2010-03-01
US20060155128A1 (en)	2006-07-13
NO20073806L (no)	2007-09-27
HRP20080113T3 (hr)	2008-04-30
HN2010000430A (es)	2012-03-26
JP2008526882A (ja)	2008-07-24
ATE446293T1 (de)	2009-11-15
US20070078150A1 (en)	2007-04-05
WO2006083491A3 (en)	2007-01-18
EP1911756A2 (en)	2008-04-16
EP1911756A3 (en)	2008-06-18
AR054320A1 (es)	2007-06-20
DE602006000339D1 (de)	2008-01-31
CR9225A (es)	2008-01-21
CN101115740A (zh)	2008-01-30
SI1732562T1 (sl)	2008-04-30
NI200700169A (es)	2008-06-25
DK1911756T3 (da)	2010-02-08
CY1109696T1 (el)	2014-08-13
PT1732562E (pt)	2008-03-18
MX2007008402A (es)	2007-09-06
UA89812C2 (ru)	2010-03-10
GT200600006A (es)	2006-08-23
HK1112241A1 (en)	2008-08-29
CA2594466A1 (en)	2006-08-10
EP1911756B9 (en)	2010-05-26
GEP20094828B (en)	2009-11-25
EP1911756B1 (en)	2009-10-21
US20070167473A1 (en)	2007-07-19
PL1911756T3 (pl)	2010-03-31
NZ556220A (en)	2011-01-28
AU2006211583C1 (en)	2011-09-08
ATE381558T1 (de)	2008-01-15
RS51007B (sr)	2010-10-31
AU2006211583B2 (en)	2011-01-27
DE602006000339T2 (de)	2009-01-22
HN2006000969A (es)	2010-03-29
AU2006211583A1 (en)	2006-08-10
PT1911756E (pt)	2009-12-22
BRPI0606704A (pt)	2008-03-11

Publication	Publication Date	Title
DK1911756T3 (da)	2010-02-08	Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil
DK1756084T3 (da)	2009-03-23	Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
DK2311464T3 (da)	2013-05-13	Midler til forebyggelse og behandling af lidelser, som involverer modulation af RyR-receptorerne
DK1644357T3 (da)	2008-04-21	Trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af lidelser relateret dertil
DK1888595T3 (da)	2012-05-29	Spiro-oxindolforbindelser og deres anvendelser som terapeutiske midler
DK2102169T3 (da)	2012-08-27	Indazolylamidderivater til behandling af glucocorticoidreceptormedierede forstyrrelser
DK1928886T3 (da)	2011-07-11	Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser
DK1805312T3 (da)	2009-10-19	Fremgangsmåder og midler til fremstilling af hyaluronan
PT1881823E (pt)	2015-03-02	Composições e métodos para o tratamento de transtornos oculares
DK1996557T3 (da)	2010-05-10	Pyridazinon-forbindelse og anvendelse deraf som herbicid
DK2051976T3 (da)	2010-09-20	4-[5-Methoxy-6-(2-methyl-6[1,2,4)triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidin-1-carboxylsyre-isopropylester som modulator af metabolisme og behandling af lidelser beslægtet dermed
DK1928879T3 (da)	2013-05-21	Kondenserede heterocykliske forbindelser og anvendelse heraf som kinase-modulatorer
DK2084151T3 (da)	2013-09-02	Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK1812110T3 (da)	2013-09-16	Apparat til behandling af dermatologiske lidelser
DK1877232T3 (da)	2014-08-11	Fremgangsmåde til behandling af træoverflader
DK1856042T3 (da)	2012-09-17	Substituerede gamma-lactamer som terapeutiske midler
PL1636190T3 (pl)	2012-10-31	Trwały kryształ związku 4-oksochinoliny
DK1708992T3 (da)	2007-11-05	Sulfonamidderivater til behandling af sygdomme
DK3403657T3 (da)	2022-02-28	Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1491212T3 (da)	2012-10-29	Middel til behandling af søvnforstyrrelser
PT2982372T (pt)	2020-10-09	Agentes moduladores do glutamato no tratamento de distúrbios mentais
DK1740530T3 (da)	2017-01-09	Substituerede phenoxy- og phenylthioderivater til behandling af proliferative forstyrrelser
HRP20150320T1 (xx)	2015-07-03	Formulacije i metode za lijeäśenje amiloidoze
DK1907374T3 (da)	2012-10-15	Til behandling af gastrointestinale sygdomme anvendelige benzylpiperazin-derivater
DK4070800T3 (da)	2025-01-02	Cladribinkur til behandling af multipel sklerose